Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Kevin Sayer to its board of directors. Mr. Sayer is former CEO of Dexcom, Inc. and current Executive Chairman of the Dexcom board, with decades of strategic leadership experience in digital health technology.
Kevin Sayer’s Role in Innovating Cancer Care
“We are excited to welcome Kevin Sayer to Guardant’s board,” said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. “Kevin has played a pivotal role in advancing innovations that have transformed how people monitor and manage disease and has a strategic and operations record delivering significant growth. His expertise will be invaluable to Guardant as we continue to pioneer innovations in how we screen, monitor, and treat disease.”
“Guardant’s leadership in liquid biopsy puts it in a powerful position to shape the next era of cancer care and disease detection, where AI can turn increasingly rich molecular data into more precise, actionable insights,” said Mr. Sayer. “I’m excited to work with the team to build on that leadership and help bring the benefits of earlier detection and more personalized treatment to more patients.”
Mr. Sayer has served as Executive Chair of the Dexcom board since 2026, as Chairman of the Board since 2018, and as a director on the board since 2007. Additionally, Mr. Sayer served as CEO of Dexcom from 2015 to 2026, and as a Dexcom executive since 2011. Prior to his roles at Dexcom, Mr. Sayer served as CFO of Biosensors International Group, Ltd., as an independent healthcare and medical technology industry consultant, as EVP and CFO of Specialty Laboratories, Inc., and as CFO of MiniMed, Inc. Mr. Sayer is a Certified Public Accountant (inactive) and received his Master’s Degree in Accounting and Information Systems concurrently with a B.A., both from Brigham Young University.